Key clinical point:
Major finding: Patients who achieved MRD-negative complete remission had an improved median disease-free survival at 7.6 months versus 0.8 months (P less than .0001)
Study details: A retrospective analysis including 53 patients with ALL who had bone marrow or extramedullary disease at baseline and had received CD19 CAR T cells at or under the maximum tolerated dose at least 1 year prior to this analysis.
Disclosures: Researchers reported financial ties to Juno Therapeutics, Cell Medica, Celgene, Eureka Therapeutics, Genentech/Roche, Gilead Sciences, Kite Pharma, Novartis, and others.
Source: Hay KA. ASCO 2018 (annual meeting of the American Society of Clinical Oncology), Abstract 7005.
Hay KA. ASCO 2018 (annual meeting of the American Society of Clinical Oncology), Abstract 7005.
This Week's Must Reads
Genetic key to bleeding risk with warfarin, Perera MA et al. JAMA. 2018 Oct 23. doi: 10.1001/jama.2018.14955
Auto-HSCT plus ablation in severe scleroderma, Sullivan KM et al. ACR Annual Meeting, Abstract 1820
Age is an independent predictor of mortality after transplant, Kyriakou C et al. Biol Blood Marrow Transplant. 2018 Sep 13. doi: 10.1016/j.bbmt.2018.08.025
Bortezomib plus VR-CAP looks promising in untreated MCL, Robak T et al. Lancet Oncol. 2018 Oct 19. doi: 10.1016/S1470-2045(18)30685-5
Complications in EPOCH-R versus R-CHOP, David RJ et al. Clin Lymphoma Myeloma Leuk. 2018 Aug 29. doi: 10.1016/j.clml.2018.08.014